Hepatocellular carcinoma (HCC) is the third leading cause of cancer death worldwide.
Surveillance for HCC is critical for early detection and treatment, but fewer than one-quarter …

Background & Aims Seroclearance of hepatitis B surface antigen (HBsAg) is a marker for
clearance of chronic hepatitis B virus (HBV) infection, but reported annual incidence rates of …

Background & Aims Tenofovir disoproxil fumarate (TDF) and entecavir are recommended as
first-line treatments for chronic hepatitis B virus (HBV) infection. However, there is debate …

Background & Aims A recent study in Asian patients with chronic hepatitis B (CHB) reported
that the incidence of hepatocellular carcinoma (HCC) was lower in patients treated with …

Background and Aims Chronic hepatitis B (CHB) can lead to hepatocellular carcinoma
(HCC). While both tenofovir disoproxil (TDF) and entecavir (ETV) have been shown to …

Background Safety profile of nucleos (t) ide analogues is an important issue in view of its
widespread use for decades in patients with chronic hepatitis B (CHB). Aim To review and …

Background Several risk scores have been recently developed to predict hepatocellular
carcinoma (HCC) in chronic hepatitis B (CHB) patients. We systematically assessed the …

The introduction of more efficient antiviral drugs are common cause drug-induced acute
kidney injury (AKI). The true prevalence of antiviral drugs induced nephrotoxicity is hardly …

Background & Aims The aim of our study was to characterize the performance of
hepatocellular carcinoma (HCC) prediction models in chronic hepatitis B (CHB) patients …

Nucleos (t) ide analogues with high barrier to resistance are regarded as the principal
therapeutic option for chronic hepatitis B (CHB). Treatment with entecavir (ETV), tenofovir …